To investigate the ventricular expression of atrial natriuretic peptide (ANP) in human hypertrophic hearts, we conducted an immunohistochemical study of 130 endomyocardial biopsy specimens obtained from the right side of the ventricular septum (RVB), left ventricular free wall (LVB), or both from a total of 80 patients: 44 patients with hypertrophic cardiomyopathy (HCM), 14 with apical hypertrophic cardiomyopathy (APH), 13 with hypertensive hearts (HHD), and nine without hypertrophy (controls). No patients had apparent congestive heart failure. ANP was not seen in ventricular myocytes in controls but was identified in biopsy specimens of hypertrophic hearts, and its distribution was characteristic in each hypertrophic group: 15 RVB (37%) and two LVB (7%) of the HCM group, one RVB (7%) and two LVB (18%) of the APH group, and zero RVB (0%/) and five LVB (46%) of the HHD group. Clinical data (including echocardiographic, hemodynamic, and angiographic data) were not directly related to ventricular ANP expression in HCM, APH, or HHD with one exception. In HHD patients, LVB specimens with ANP showed greater ventricular wall thickness than LVB specimens without ANP. According to histological data, however, the ANP-present RVB specimens of HCM or ANP-present LVB specimens of HHD had greater myocyte size than did the ANP-absent specimens. In addition, in HCM patients, the ANP-present RVB specimens showed more severe fibrosis and myofiber disarray than did the ANP-absent specimens. We conclude that a failing state and hemodynamic overload are not likely to be indispensable for ANP expression in human hypertrophic ventricles and that ventricular ANP expression occurs as a response to disease-specific changes: hemodynamic overload in HHD and histological changes such as myocardial fiber disarray, hypertrophy of myocytes, and fibrosis in HCM, which may reflect the characteristic distribution of intraventricular ANP. (Circulation 1991;83:181-190) A trial natriuretic peptide (ANP) is a circulating hormone regulating body fluids, electrolytes, and vascular homeostasis, which is produced and secreted predominantly by the atria in healthy
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Methods

Patient Profile
Endomyocardial biopsy specimens, taken from the right side of the ventricular septum (RVB) or left ventricular free wall (LVB), or both, from a total of 80 patients were used. There were 62 male and 18 female patients, ranging in age from 14 to 71 years. All patients were evaluated clinically by both noninvasive and invasive methods. Based on clinical, echocardiographic, hemodynamic, angiographic, and histological findings, the patients were assigned to the following four groups: asymmetrical ventricular septal hypertrophy due to classic hypertrophic cardiomyopathy (HCM, 44 patients), ventricular apical hypertrophy due to apical hypertrophic cardiomyopathy without asymmetrical septal hypertrophy (APH of so-called Japanese type, 14 patients), ventricular concentric hypertrophy due to chronic systemic hypertension (HHD, 13 patients), and "controls" without ventricular hypertrophy (nine patients). The diagnosis of HCM was made principally according to the definition and classification proposed by the World Health Organization/International Society and Federation of Cardiology task force.25 APH was diagnosed based on the characteristic electrocardiographic (giant negative T waves), echocardiographic (hypertrophy confined mainly to the apical part of the left ventricle), and left ventriculographic (ace of spades-shaped at end diastole) findings. 26, 27 The HHD group included patients who had clear-cut histories of chronic hypertension for 5-15 years or more (>160/95 mm Hg), whose hearts were recognized as hypertrophic by cardiac imagings and whose biopsy findings ruled out any infiltrative heart disease. Four of these patients were treated with calcium antagonists or adrenergic blocking agents (n =3) or thiazide-type diuretics (n-I). The control group included patients who had been clinically suspected of having some cardiac disease because of chest pain, syncope, minimal electrocardiographic change, or arrhythmia, but for whom both noninvasive and invasive examinations, including coronary angiography, and biopsy findings were not diagnostic. History of hypertension was not evident in any patients from the three groups other than the HHD group. Patients with severe coronary arterial stenosis (>75% luminal narrowing) were excluded from this study. No patient had apparent history or clinical findings of congestive heart failure; all patients were categorized as New York Heart Association functional class I; and all patients were not receiving drugs on the day of invasive examination. There were no significant differences in age or gender distribution among the four groups.
Echocardiographic, Hemodynamic, and Angiographic Evaluations
In all patients, the two-dimensional echocardiographic study was performed within 1 week before invasive examination. The ventricular septal thickness and the left ventricular free wall thickness at diastolic phase were recorded at the midventricular level.
After premedication with 5 mg diazepam, all patients underwent both rightand left-heart catheterization, biplane left ventriculography, and selective coronary angiography with standard techniques. The heart rate and pressures from the right and left heart were recorded, and the cardiac index was estimated by the thermodilution method. Left ventricular end-diastolic and end-systolic volume indexes and the ejection fraction were calculated from the left ventricular cineangiogram performed in the right anterior oblique projection by the method of Kennedy et al.28 Endomyocardial Biopsy Procedure Biopsy specimens were obtained during cardiac catheterization. They were taken from the RVB or LVB, or both by a Konno-Sakakibara29 or Kawai30 biopsy catheter. From each patient, two or three biopsy specimens were obtained from both RVB and LVB, RVB only, or LVB only. The biopsy procedure was performed from both RVB and LVB, RVB only, and LVB only, respectively, in 24, 17, and 3 patients with HCM, in 11, 3, and 0 patients with APH, in 10, 2, and 1 patients with HHD, and in 5, 3, and 1 controls.
Thus, the biopsy specimens used in this study consisted of a total of 130 specimens (74 RVB and 55 LVB): 41 RVB and 27 LVB from the HCM patients, 14 RVB and 11 LVB from the APH patients, 12 RVB and 11 LVB from the HHD patients, and eight RVB and six LVB from the controls ( Table 1) .
Histological Evaluation
The biopsy specimens were immediately fixed with a 10% buffered formalin solution, dehydrated, embedded in paraffin, and cut into 4-or 25-/m thick sections. From light microscopic observations of the sections stained with hematoxylin-eosin or Masson's trichrome, histological parameters such as myocyte size (mean diameter, 30-50 myocytes per specimen), degree of fibrosis (from 0 to 3), and degree of myofiber disarray (from 0 to 3) were evaluated. The extent of fibrosis was graded as 0 (no fibrosis), 1 (mild, when an isolated scar or mild interstitial fibrous tissue formation, or both, was identified), 2 (moderate, intermediate between mild and severe), or 3 (severe, characterized by extreme replacement Control  9  5  3  1  8  6  HCM  44  24  17  3  41  27  APH  14  11  3  0  14  11  HHD  13  10  2  1  12  11  Total  130  50  25  5  75 55 RVB, biopsy specimen from the right side of the ventricular septum; LVB, biopsy specimen from the left ventricular free wall; HCM, hypertrophic cardiomyopathy; APA, apical hypertrophic cardiomyopathy; HHD, hypertension.
scarring occupying substantial portions of the section).22 For myocardial fiber disarray, the abnormal disarray defined in our previous reports,3132 was graded according to the severity and the extent of the finding in the 4-and 25 -,m thick sections as follows: 0 (no myofiber disarray), 1 (mild, only minimal and focal myofiber disarray), 2 (moderate, intermediate between mild and severe), and 3 (severe disorientation of myofibers covering more than three quarters of a section).33 Two observers in a blinded fashion reviewed the sections, and the variability between the observers was 0.05±0.36 regarding the grade of fibrosis and 0.06±0.33 for the grade of disarray. Immunohistochemical Procedure and Evaluation A monoclonal antibody to a-human ANP was prepared as previously described. 34 The recognized epitope of the monoclonal antibody is located in the N-terminal half of the ring structure of a-human ANP including Met12 residue. This radioimmunoassay can recognize not only a-human ANP but also p8-human ANP with a cross-reactivity of 80% on a molar basis, and y-human ANP on an equimolar basis.34
Immunohistochemical reactions according to an indirect immunoperoxidase method35 were performed on the 4-,um thick sections of biopsy specimens with some technical modifications. Intrinsic peroxidase activity was inhibited by the addition of 0.3% hydrogen peroxidase in 0.01 mol/l phosphate buffered saline, and nonspecific binding was blocked with normal goat serum. The addition of the hydrogen peroxidase solution required as much as 20 minutes. As the primary antibody, the monoclonal antibody was added (dilution of the ascite, 1:1000, vol: vol) to the sections for 48 hours at 4°C. In the second step, peroxidase conjugated F(ab')2 fragment of the secondary antibody (goat antimouse immunoglobulin G(H+L) (Jackson Immunoresearch Laboratories, Inc., at a dilution of 1:750, vol:vol) was added for 45 minutes at room temperature. Then, the sections were stained with 45 mg 3,3'-diaminobenzidine tetrahydrochloride (Sigma Chemical Co., St. Louis) and 0.05% hydrogen peroxide in 100 ml 0.05 mol/l Tris buffer solution for 3 minutes at room temperature. Between each step, the sections were washed four times (10 minutes each) with 0.01 mol/l phosphate buffered saline. Finally, counterstaining with hematoxylin was performed. The specificity of the immunologic reactions was controlled by replacing the primary antibody with normal mouse serum or with phosphate buffered saline. As a positive control section, a tissue preparation of the right atrial appendage was obtained from a patient during aortocoronary bypass surgery.
Immunohistochemical staining was performed on the two largest and different specimens taken from the ventricular side of the same heart and on sections from three different depths of the same specimen. The presence of immunoreactive ANP was assessed by light microscopy. Two observers who were unaware of which group the sections belonged reviewed the sections and graded ANP in each specimen as present or absent. The ANP-present specimens (for RVB or LVB) were defined as those that contained at least one ANP-present section. Unanimity on the grade of ANP was acquired among the two observers for all sections.
Plasma ANP Measurement
Acquisition of blood samples for plasma ANP measurement, within 2 weeks before the biopsy procedure, was possible in 17 patients: 7 HCM, 4 APH, 2 HHD, and 4 controls. Blood samplings were obtained from an antecubital vein while the patient was in a recumbent position after an overnight fast. Extraction of ANP from plasma was performed with a Sep-Pak C18 cartridge (Waters Associates Inc., Milford, Mass.), and measurement of plasma ANP levels was performed with the specific radioimmunoassay for ANP as previously reported.5,21 This radioimmunoassay recognizes a COOH-terminal portion of a-human ANP(17-28). Cross-reactivities with (3-human ANP and y-human ANP were 120% and 100%, respectively, on a molar basis.
Statistical Analysis
Clinicopathological data were expressed as mean-+±SD. Statistical comparisons were performed with x2 analysis, Student's t test, or a one-way analysis of variance with multiple comparisons when appropriate. Statistical significance was designated at a probability value less than 0.05. LVEDVI and LVESVI, left ventricular end-diastolic and end-systolic volume indexes; VST and LVT, ventricular septal and left ventricular posterior wall thickness; LVSP and LVEDP, left ventricular peak systolic and end-diastolic pressure; RVSP and RVEDP, right ventricular peak systolic and end-diastolic pressure; EF, ejection fraction; CI, cardiac index; ANP, atrial natriuretic peptide; HCM, hypertrophic cardiomyopathy; APH, apical hypertrophic cardiomyopathy; HHD, hypertension. *p<0.01, tp<0.05 vs. control group (one-way analysis of variance with multiple comparisons). Table 2 summarizes the clinical, echocardiographic, hemodynamic, and angiographic data on the patients. Echocardiographic and left ventriculographic evaluations revealed significantly hypertrophic ventricles in the HCM, APH, and HHD groups compared with the controls. No differences occurred in the left ventricular volume indexes (at end systole and end diastole), right ventricular pressures, ejection fraction, or cardiac index among the four groups. However, left ventricular end-diastolic pressure was significantly higher in the HCM and APH groups than in the control group, and left ventricular systolic pressure was higher in the HHD group than in the control group. Ten of the 44 HCM patients showed left ventricular outflow tract obstruction, and their pressure gradients averaged 72±30 mm Hg. Mean plasma ANP concentration of the HCM group was significantly higher than that of the control group. Table 3 summarizes the histological data on the biopsy specimens. Both RVB and LVB or LVB of the groups of diseased hearts had significantly greater myocyte size or more severe fibrosis than that of the control group. The degree of myofiber disarray was significantly greater in the HCM and APH groups than in the control group in both RVB and LVB. In the control group and the APH and HHD groups, the myocyte size was significantly greater in LVB than in RVB, whereas a difference was not seen in the HCM group. In the HCM group, myofiber disarray was more severe in RVB than in LVB.
Results
Immunohistochemical Expression ofANP
ANP was observed as a fine granular, dark-brown immunoreactive substance in the cytoplasm of ventricular myocytes in hypertrophic hearts (Figure 1 ). It tended to concentrate around the nuclei, but it was also widely distributed in the peripheral cytoplasm. Lipofuscin granules were much bigger in size and not dark brown and, therefore, could be easily distinguished from ANP granules. No immunopositive substances were seen in the endocardium or in any of the connective tissues. The sections without primary antibody did not show any immunoreactivity. The tissue preparation from the right atrial appendage as an ANP-positive control section showed very strong immunoreactivity in the cytoplasm of the myocytes (Figure 1 ). 
Ventricular ANP Expression and Distribution in Four Groups
None of the specimens from the control group, eight from RVB, and six from LVB showed ANP immunoreactivity. However, ANP was present in 15 of 41 RVB (37%) and in two of 27 LVB (7%) from the HCM group, in one of 14 RVB (7%) and in two of 11 LVB (18%) from the APH group, and in none of 12 RVB (0%) and in five of 11 LVB (45%) from the HHD group. The incidence of ANP presence was significantly greater in RVB of the HCM group than in RVB of the other groups and was significantly greater in LVB of the HHD group than in LVB of the normal and HCM groups. In HCM patients, ANP was predominant in RVB, whereas in the HHD group, it was predominant in LVB. There was no significant difference in the incidence of ANP-present specimens in both RVB and LVB between the HCM patients with and without left ventricular outflow tract: five of 10 RVB and none of five LVB from 10 patients with obstruction and 10 of 31 RVB and two of 22 LVB from 34 patients without obstruction (X2 analysis) (see Table 4 ).
Comparison of Clinicopathological Parameters Between the Patients or Biopsy Specimens With and Without Ventricular ANP Expression
In Table 5 , comparisons of clinical values are shown for the specimens with and without ANP expression in RVB and for the specimens with and without ANP expression in LVB. Both the ventricular septum and free wall were thicker in specimens with ANP in LVB of the HHD group. However, the other parameters were not different between the ANP-present and ANP-absent specimens of the HHD group. In the HCM and APH groups, clinical values were not different between ANP-present and ANP-absent specimens. When analyzed in all specimens, the plasma ANP level was higher for those with ANP in RVB than in those without ANP in RVB (Table 5) Histological data of RVB and LVB for each group are shown separately in the ANP-present and ANPabsent specimens in Table 6 . In RVB of HCM and in LVB of the HHD group, the myocyte size was greater in the ANP-present specimens than in the ANP-absent specimens. The ANP-present RVB of the HCM group showed more severe grades of fibrosis and myofiber disarray than did the ANP-absent specimens. When analyzed in all specimens, these three parameters were greater in the RVB specimens with ANP than in those without ANP, and the myocyte size and degree of fibrosis were greater in the LVB specimens with ANP than in those without ANP (Table 6 ).
Discussion
Myocardial hypertrophy is likely to be closely associated with ANP or ANP gene expression in the ventricles of both animal models and humans.11 [22] [23] [24] Myocardial hypertrophy is accepted as one of several compensatory mechanisms of the normal heart to reduced contractility or hemodynamic overloads as well as the Frank-Starling mechanism and increased catecholamine levels.36 ANP has been reported to have a beneficial effect on human failing hearts.37 Thus, concomitant occurrence of myocardial hypertrophy and augmentation of ANP expression as an adaptation (compensation) to stress has been suggested in human ventricles. 21, 22 Recent studies have shown augmented ANP or ANP gene expression in human ventricles under failing states: in hearts with dilated cardiomyopathy, in those with valvular heart disease, and in those with myocardial infarction. [17] [18] [19] [20] [21] [22] Meanwhile, some reports on animal models suggested the possibility that ventricular ANP gene induction is a marker of myocardial hypertrophy rather than an adaptive response.2324 In this study, we have shown augmented ANP expression in the ventricular septum of HCM that is accompanied by hypertrophy but not by apparent hemodynamic overloads. The result indicates that in adult human ventricles, a hemodynamic failing state is not indispensable for the augmentation of ANP expression.
Augmentation of plasma ANP, ventricular ANP, or ANP gene has been well documented in some animal models with chronic hypertension.14,1 Also, in patients with chronic systemic hypertension, high levels of plasma ANP have been shown.38-40 To our knowledge, however, this is the first report to immunohistochemically document augmented ventricular ANP expression in human hypertensive hearts. In a previous study of failing ventricles in dilated cardiomyopathy or of old myocardial infarction, we hypothesized that augmentation of ventricular ANP and ANP gene expression was caused by an increase in afterload or preload on the ventricle.21 Left ventricular concentric hypertrophy is one of the representative features of the hypertensive heart and is regarded as a result of an adaptive response to excessive wall tension. 41 In general, therefore, the greater the hypertrophy of the ventricles, the longer the duration and stronger the wall tension. The present study shows that the HHD patients with ventricular ANP expression had more severe hypertrophy of the left ventricle than did patients without ANP expression. Moreover, ANP-present myocytes were found only in LVB (the endocardial side of the left ventricle where wall tension is strongest) and not in RVB (as the epicardial side of the left ventricle). These results support the "hemodynamic overloads" hypothesis for ventricular ANP expression.
In this study, we found ventricular ANP augmentation in HCM patients. Contrary to the HHD group, the distribution was characteristically inclined toward RVB rather than LVB specimens. RVB specimens are drawn from the right ventricular cavity of the low-pressure system. The right ventricle of HCM possesses neither pressure nor volume overload, but HCM has rather a low range of peak systolic and end-diastolic wall stress.42 Although elevated left ventricular end-diastolic pressure was seen in HCM, it showed no relation with ANP expression, nor did the other hemodynamic parameters. On the other hand, ANP-present specimens in RVB of HCM patients showed significantly more severe histological changes, that is, greater myocyte sizes, a higher degree of fibrosis, and a higher degree of myofiber disarray than did ANP-absent specimens. It is well known that in the autopsied hearts with HCM, the extent of fibrosis and the extent of myofiber disarray are greater in the ventricular septum than in the left ventricular free wall.3132 43 In the present study, myofiber disarray was significantly more severe in RVB than in LVB. We previously reported that myofiber disarray in hearts with HCM involved a large number of myocardial fibers running in a vectorically perpendicular direction to the left ventricu- 32 Theoretically, the contraction of fibers running in a perpendicular direction would make the wall thinner and the cavity larger (systole), and the relaxation of fibers would make the wall thicker and the cavity smaller (diastole). The wall, with a considerable number of fibers running in the vectorically perpendicular direction, would be hypofunctional even without hemodynamic loads. Such would account for the relative lack of systolic septal thickening. Furthermore, an abnormal alignment of fibers in the area with disarray would be expected to cause focal, greater and uneven tension in the tissue. Fibrosis disrupting the myofiber running direction would also affect the tissue as well. In addition to the regional mechanical effects, disarray may also represent a genetic predisposition for HCM that is present long before hypertrophy or overload occurs. Thus, in HCM, ANP augmentation in the ventricular septum does not occur as an adaptive response to hemodynamic overload but as a response to regional histological changes, such as myocardial fiber disarray, hypertrophy of myocytes, or fibrosis.
APH was described in Japan for the first time, but it is still controversial whether APH is a subtype of classic HCM.2627 Recent studies suggest that this disease consists of two types: so-called Japanese type and another.4445 Detailed histological descriptions of the Japanese type APH are not yet conclusive.27. 46, 47 Biopsy findings from APH used in this study showed milder histological changes in RVB and similar histological findings in LVB compared with those from classic HCM (Table 6 ). ANP expression in RVB was rarely noted in the APH and was different from that in classic HCM. The low frequency may be related to milder histological changes in APH compared with that of HCM.
The mean plasma ANP level of the seven HCM patients in this study was significantly higher than that of the controls. However, it was not as high as that of patients with severe congestive heart failure compared with our previous report (1,600±+1,098 pg/ml; n=7; p<0.05).48 Our present data demonstrate that the plasma ANP level was higher in patients with ANP expression in the ventricle (in RVB) than in those without ANP expression. This suggests the possible contribution of ventricular ANP to the level of systemic ANP in HCM patients, although it may not be as considerable as in patients with severe congestive heart failure. 37 Thus, further approaches should be expected on the significance of pathophysiological roles of ANP in human hypertrophic ventricles.
Conclusion
We immunohistochemically identified the augmented expression of ANP in hypertrophic ventricular myocardium obtained from HHD and HCM patients. ANP was more frequently expressed in LVB in cases of HHD, whereas it was more frequent in RVB in cases of HCM. This disease-specific, characteristic distribution of ANP may be due to the difference in the main triggers for ANP expression: a mechanical stimulus caused by hemodynamic overloads in HHD and expression caused by regional histological changes in HCM.
